Role of macrophage TRPV4 in inflammation


Transient receptor ion channels have emerged as immensely important channels/receptors in diverse physiological and pathological responses. Of particular interest is the transient receptor potential channel subfamily V member 4 (TRPV4), which is a polymodal, nonselective, calcium-permeant cation channel, and is activated by both endogenous and exogenous stimuli. Both neuronal and nonneuronal cells express functional TRPV4, which is responsive to a variety of biochemical and biomechanical stimuli. Emerging discoveries have advanced our understanding of the role of macrophage TRPV4 in numerous inflammatory diseases. In lung injury, TRPV4 mediates macrophage phagocytosis, secretion of pro-resolution cytokines, and generation of reactive oxygen species. TRPV4 regulates lipid-laden macrophage foam cell formation, the hallmark of atheroinflammatory conditions, in response to matrix stiffness and lipopolysaccharide stimulation. Accumulating data also point to a role of macrophage TRPV4 in the pathogenesis of the foreign body response, a chronic inflammatory condition, through the formation of foreign body giant cells. Deletion of TRPV4 in macrophages suppresses the allergic and nonallergic itch in a mouse model, suggesting a role of TRPV4 in skin disease. Here, we discuss the current understanding of the role of macrophage TRPV4 in various inflammatory conditions.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Liedtke W. Molecular mechanisms of TRPV4-mediated neural signaling. Ann N Y Acad Sci. 2008;1144:42–52.

  2. 2.

    Liedtke W, Friedman JM. Abnormal osmotic regulation in trpv4-/- mice. Proc Natl Acad Sci USA. 2003;200:13698–703.

  3. 3.

    Liedtke W, Tobin DM, Bargmann CI, Friedman JM. Mammalian TRPV4 (VR-OAC) directs behavioral responses to osmotic and mechanical stimuli in Caenorhabditis elegans. Proc Natl Acad Sci USA. 2003;100:14531–6.

  4. 4.

    Suzuki M, Mizuno A, Kodaira K, Imai M. Impaired pressure sensation in mice lacking TRPV4. J Biol Chem. 2003;278:22664–8.

  5. 5.

    Everaerts W, Nilius B, Owsianik G. The vanilloid transient receptor potential channel TRPV4: from structure to disease. Prog Biophys Mol Biol. 2010;103:2–17.

  6. 6.

    Garcia-Elias A, Mrkonjić S, Jung C, Pardo-Pastor C, Vicente R, Valverde MA. The trpv4 channel. Handb Exp Pharmacol. 2014;222:293–319.

  7. 7.

    Auer-Grumbach M, Olschewski A, Papić L, Kremer H, McEntagart ME, Uhrig S, et al. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet. 2010;42:160–4.

  8. 8.

    Adapala RK, Thoppil RJ, Luther DJ, Paruchuri S, Meszaros JG, Chilian WM, et al. TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J Mol Cell Cardiol. 2013;54:45–52.

  9. 9.

    Du J, Wang X, Li J, Guo J, Liu L, Yan D, et al. Increasing TRPV4 expression restores flow-induced dilation impaired in mesenteric arteries with aging. Sci Rep. 2016;6:22780.

  10. 10.

    Goswami R, Merth M, Sharma S, Alharbi MO, Aranda-Espinoza H, Zhu X, et al. TRPV4 calcium-permeable channel is a novel regulator of oxidized LDL-induced macrophage foam cell formation. Free Radic Biol Med. 2017;110:142–50.

  11. 11.

    Goswami R, Cohen J, Sharma S, Zhang DX, Lafyatis R, Bhawan J, et al. TRPV4 ion channel is associated with scleroderma. J Investig Dermatol. 2016;137:962–5.

  12. 12.

    Köhler R, Heyken WT, Heinau P, Schubert R, Si H, Kacik M, et al. Evidence for a functional role of endothelial transient receptor potential V4 in shear stress-induced vasodilatation. Arterioscler Thromb Vasc Biol. 2006;26:1495–502.

  13. 13.

    Lamandé SR, Yuan Y, Gresshoff IL, Rowley L, Belluoccio D, Kaluarachchi K, et al. Mutations in TRPV4 cause an inherited arthropathy of hands and feet. Nat Genet. 2011;43:1142–6.

  14. 14.

    Sharma S, Goswami R, Merth M, Cohen J, Lei KY, Zhang DX, et al. TRPV4 ion channel is a novel regulator of dermal myofibroblast differentiation. Am J Physiol Cell Physiol. 2017;312:C562–C572.

  15. 15.

    Mochizuki T, Sokabe T, Araki I, Fujishita K, Shibasaki K, Uchida K, et al. The TRPV4 cation channel mediates stretch-evoked Ca2+ influx and ATP release in primary urothelial cell cultures. J Biol Chem. 2009;284:21257–64.

  16. 16.

    Thodeti CK, Matthews B, Ravi A, Mammoto A, Ghosh K, Bracha AL, et al. TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin to integrin signalling. Circ Res. 2009;104:1123–30.

  17. 17.

    Loukin S, Zhou X, Su Z, Saimi Y, Kung C. Wild-type and brachyolmia-causing mutant TRPV4 channels respond directly to stretch force. J Biol Chem. 2010;285:27176–81.

  18. 18.

    Strotmann R, Harteneck C, Nunnenmacher K, Schultz G, Plant TD. OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol. 2000;2:695–702.

  19. 19.

    Liedtke W, Choe Y, Marti-Renom MA, Bell AM, Denis CS, Sali A, et al. Vanilloid receptor-related osmotically activated channel (VROAC), a candidate vertebrate osmoreceptor. Cell. 2000;103:525–35.

  20. 20.

    O’Neil RG, Heller S. The mechanosensitive nature of TRPV channels. Pflugers Arch. 2005;451:193–203.

  21. 21.

    Güler A, Lee H, Shimizu I, Caterina MJ. Heat-evoked activation of TRPV4 (VR-OAC). J Neurosci. 2002;22:6408–14.

  22. 22.

    Vriens J, Watanabe H, Janssen A, Droogmans G, Voets T, Nilius B. Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. Proc Natl Acad Sci USA. 2004;101:396–401.

  23. 23.

    Chung MK, Lee H, Caterina MJ. Warm temperatures activate TRPV4 in mouse 308 keratinocytes. J Biol Chem. 2003;278:32037–46.

  24. 24.

    Chung MK, Lee H, Mizuno A, Suzuki M, Caterina MJ. TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. J Biol Chem. 2004;279:21569–75.

  25. 25.

    Grace MS, Lieu T, Darby B, Abogadie FC, Veldhuis N, Bunnett NW, et al. The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo. Br J Pharmacol. 2014;171:3881–94.

  26. 26.

    Zheng X, Zinkevich NS, Gebremedhin D, Gauthier KM, Nishijima Y, Fang J, et al. Arachidonic acid-induced dilation in human coronary arterioles: convergence of signaling mechanisms on endothelial TRPV4-mediated Ca2 entry. J Am Heart Assoc. 2013;2:e000080.

  27. 27.

    Zhang DX, Mendoza SA, Bubolz AH, Mizuno A, Ge ZD, Li R, et al. Transient receptor potential vanilloid type 4-deficient mice exhibit impaired endothelium-dependent relaxation induced by acetylcholine in vitro and in vivo. Hypertension. 2009;53:532–8.

  28. 28.

    Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, et al. Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes. J Clin Investig. 2014;124:3713–24.

  29. 29.

    Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012;4:159ra148.

  30. 30.

    Hamanaka K, Jian MY, Weber DS, Alvarez DF, Townsley MI, Al-Mehdi AB, et al. TRPV4 initiates the acute calcium-dependent permeability increase during ventilator-induced lung injury in isolated mouse lungs. Am J Physiol Lung Cell Mol Physiol. 2007;293:L923–32.

  31. 31.

    Everaerts W, Zhen X, Ghosh D, Vriens J, Gevaert T, Gilbert JP, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci USA. 2010;107:19084–9.

  32. 32.

    Masuyama R, Vriens J, Voets T, Karashima Y, Owsianik G, Vennekens R, et al. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metabol. 2008;8:257–65.

  33. 33.

    Rahaman SO, Grove LM, Paruchuri S, Southern BD, Abraham S, Niese KA, et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. J Clin Investig. 2014;124:5225–38.

  34. 34.

    Okada Y, Shirai K, Miyajima M, Reinach PS, Yamanaka O, Sumioka T, et al. Loss of TRPV4 function suppresses inflammatory fibrosis induced by alkali-burning mouse corneas. PLoS One. 2016;11:e0167200.

  35. 35.

    Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69.

  36. 36.

    Blakney AK, Swartzlander MD, Bryant SJ. The effects of substrate stiffness on the in vitro activation of macrophages and in vivo host response to poly(ethylene glycol)-based hydrogels. J Biomed Mater Res. 2012;100:1375–86.

  37. 37.

    Hansen L, Taylor WR. Is increased arterial stiffness a cause or consequence of atherosclerosis? Atherosclerosis. 2016;249:226–7.

  38. 38.

    Hind LE, Dembo M, Hammer DA. Macrophage motility is driven by frontal-towing with a force magnitude dependent on substrate stiffness. Integr Biol. 2015;7:447–53.

  39. 39.

    Van Goethem E, Poincloux R, Gauffre F, Maridonneau-Parini I, Le Cabec V. Matrix architecture dictates three-dimensional migration modes of human macrophages: differential involvement of proteases and podosome-like structures. J Immunol. 2010;184:1049–61.

  40. 40.

    Previtera ML, Sengupta A. Substrate stiffness regulates proinflammatory mediator production through TLR4 activity in macrophages. PLoS One. 2015;10:e0145813.

  41. 41.

    Scheraga RG, Abraham S, Niese KA, Southern BD, Grove LM, Hite RD, et al. TRPV4 mechanosensitive ion channel regulates lipopolysaccharide-stimulated macrophage phagocytosis. J Immunol. 2016;196:428–36.

  42. 42.

    Adlerz KM, Aranda-Espinoza H, Hayenga HN. Substrate elasticity regulates the behavior of human monocyte-derived macrophages. Eur Biophys J. 2016;45:301–9.

  43. 43.

    Gupta N, Goswami R, Alharbi MO, Biswas D, Rahaman SO. TRPV4 is a regulator in P. gingivalis lipopolysaccharide-induced exacerbation of macrophage foam cell formation. Physiol Rep. 2019;7:e14069.

  44. 44.

    Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metabol. 2006;4:211–21.

  45. 45.

    Balakrishna S, Song W, Achanta S, Doran SF, Liu B, Kaelberer MM, et al. TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2014;307:L158–72.

  46. 46.

    Hamanaka K, Jian MY, Townsley MI, King JA, Liedtke W, Weber DS, et al. TRPV4 channels augment macrophage activation and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2010;299:L353–62.

  47. 47.

    Zhu G, Gulsvik A, Bakke P, Ghatta S, Anderson W, Lomas DA, et al. Association of TRPV4 gene polymorphisms with chronic obstructive pulmonary disease. Hum Mol Genet. 2009;18:2053–62.

  48. 48.

    Henry CO, Dalloneau E, Pérez-Berezo MT, Plata C, Wu Y, Guillon A, et al. In vitro and in vivo evidence for an inflammatory role of the calcium channel TRPV4 in lung epithelium: potential involvement in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2016;311:L664–75.

  49. 49.

    Goswami R, Arya R, Biswas D, Zhu X, Rahaman SO. Transient receptor potential Vanilloid 4 (TRPV4) is required for foreign body response and giant cell formation. Am J Pathol. 2019;S0002-9440:30101–4.

  50. 50.

    Luo J, Feng J, Yu G, Yang P, Mack MR, Du J, et al. Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch. J Allergy Clin Immunol. 2017;141:608–19.

  51. 51.

    Melendez AJ, Tay HK. Phagocytosis: a repertoire of receptors and Ca(2+) as a key second messenger. Biosci Rep. 2008;28:287–98.

  52. 52.

    Nunes P, Demaurex N. The role of calcium signaling in phagocytosis. J Leukoc Biol. 2010;88:57–68.

  53. 53.

    Fleckenstein-Grün G, Thimm F, Czirfuzs A, Matyas S, Frey M. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. J Cardiovasc Pharmacol. 1994;24:S75–S84.

  54. 54.

    Shi H, Severs NJ, Robenek H. Effects of calcium on the migration and recruitment of macrophages and macrophage-derived foam cells. FASEB J. 1996;10:491–501.

  55. 55.

    Yang X, Zhang Y, Huang Y, Yang F. Changes of transmembrane Ca2+ gradient in the formation of macrophage-derived foam cells. Biosci Rep. 2000;20:1–12.

  56. 56.

    Rahaman SO, Zhou G, Silverstein RL. Vav protein guanine nucleotide exchange factor regulates CD36 protein-mediated macrophage foam cell formation via calcium and dynamin-dependent processes. J Biol Chem. 2011;286:36011–9.

  57. 57.

    Tang L, Gamal El-Din TM, Payandeh J, Martinez GQ, Heard TM, Scheuer T, et al. Structural basis for Ca2+ selectivity of a voltage-gated calcium channel. Nature. 2013;505:56–61.

  58. 58.

    Eisenhut M, Wallace H. Ion channels in inflammation. Pflugers Arch. 2011;461:401–21.

  59. 59.

    O’Conor CJ, Leddy HA, Benefield HC, Liedtke WB, Guilak F. TRPV4-mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading. Proc Natl Acad Sci. USA. 2014;111:1316–21.

  60. 60.

    Dos Santos CC, Slutsky AS. Invited review: mechanisms of ventilator-induced lung injury: a perspective. J Appl Physiol. 2000;89:1645–55.

  61. 61.

    Parker JC, Hernandez LA, Peevy K. Mechanisms of ventilator induced injury. Crit Care Med. 1993;21:131–43.

  62. 62.

    Eyal FG, Hamm CR, Parker JC. Reduction in alveolar macrophages attenuates acute ventilator induced lung injury in rats. Intensive Care Med. 2007;33:1212–8.

  63. 63.

    Frank JA, Wray CM, McAuley DF, Schwendener R, Matthay MA. Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2006;291:L1191–L1198.

  64. 64.

    Pairet N, Mang S, Fois G, Keck M, Kühnbach M, Gindele J, et al. TRPV4 inhibition attenuates stretch-induced inflammatory cellular responses and lung barrier dysfunction during mechanical ventilation. PLoS One. 2018;13:e0196055.

  65. 65.

    Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;3:13.

  66. 66.

    Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11:723–37.

  67. 67.

    Eddens T, Kolls JK. Host defenses against bacterial lower respiratory tract infection. Curr Opin Immunol. 2012;24:424–30.

  68. 68.

    Barth K, Remick DG, Genco CA. Disruption of immune regulation by microbial pathogens and resulting chronic inflammation. J Cell Physiol. 2013;228:1413–22.

  69. 69.

    Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Throm. Haemost. 2005;3:1800–14.

  70. 70.

    Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, et al. ‘Role reversal’ for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol. 2007;8:1303–12.

  71. 71.

    Churg A, Wang X, Wang RD, Meixner SC, Pryzdial EL, Wright JL. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol. 2007;37:144–51.

  72. 72.

    Mihara K, Ramachandran R, Saifeddine M, Hansen KK, Renaux B, Polley D, et al. Thrombin-mediated direct activation of proteinase-activated receptor-2: another target for thrombin signaling. Mol Pharmacol. 2016;89:606–14.

  73. 73.

    Rayees S, Joshi JC, Tauseef M, Anwar M, Baweja S, Rochford I, et al. PAR2-mediated cAMP generation suppresses TRPV4-dependent Ca2+ signaling in alveolar macrophages to resolve TLR4-induced inflammation. Cell Rep. 2019;27:793–805.

  74. 74.

    Li M, Fang XZ, Zheng YF, Xie YB, Ma XD, Liu XT, et al. Transient receptor potential vanilloid 4 is a critical mediator in LPS mediated inflammation by mediating calcineurin/NFATc3 signaling. Biochem Biophys Res Commun. 2019;S0006-291X:30642–4.

  75. 75.

    Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503–16.

  76. 76.

    Lusis AJ. Atherosclerosis. Nature. 2000;407:233–41.

  77. 77.

    Moore KJ, Tabas I. The cellular biology of macrophages in atherosclerosis. Cell. 2011;145:341–55.

  78. 78.

    Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13:709–21.

  79. 79.

    McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog Lipid Res. 2011;50:331–47.

  80. 80.

    Rahaman SO, Swat W, Febbraio M, Silverstein RL. Vav family Rho guanine nucleotide exchange factors regulate CD36-mediated macrophage foam cell formation. J Biol Chem. 2011;286:7010–7.

  81. 81.

    Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.

  82. 82.

    Thomas MR, Lip GY. Novel risk markers and risk assessments for cardiovascular disease. Circ Res. 2017;120:133–49.

  83. 83.

    Hayashi C, Viereck J, Hua N, Phinikaridou A, Madrigal AG, Gibson FC 3rd, et al. Porphyromonas gingivalis accelerates inflammatory atherosclerosis in the innominate artery of ApoE deficient mice. Atherosclerosis. 2011;215:52–9.

  84. 84.

    Fukasawa A, Kurita-Ochiai T, Hashizume T, Kobayashi R, Akimoto Y, Yamamoto M. Porphyromonas gingivalis accelerates atherosclerosis in C57BL/6 mice fed a high-fat diet. Immunopharmacol Immunotoxicol. 2012;34:470–6.

  85. 85.

    Chukkapalli SS, Velsko IM, Rivera-Kweh MF, Zheng D, Lucas AR, Kesavalu L. Polymicrobial oral infection with four periodontal bacteria orchestrates a distinct inflammatory response and atherosclerosis in ApoE null mice. PLoS One. 2015;10:e0143291.

  86. 86.

    Qi M, Miyakawa H, Kuramitsu HK. Porphyromonas gingivalis induces murine macrophage foam cell formation. Microb Pathog. 2003;35:259–67.

  87. 87.

    Teeuw WJ, Slot DE, Susanto H, Gerdes VE, Abbas F, D’Aiuto F, et al. Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis. J Clin Periodontol. 2014;41:70–9.

  88. 88.

    Houcken W, Teeuw WJ, Bizzarro S, Alvarez Rodriguez E, Mulders TA, van den Born BJ, et al. Arterial stiffness in periodontitis patients and controls. a case-control and pilot intervention study. J Hum Hypertens. 2016;30:24–9.

  89. 89.

    Kebschull M, Demmer RT, Papapanou PN. “Gum bug, leave my heart alone!“epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. J Dent Res. 2010;89:879–902.

  90. 90.

    Schmitt A, Carra MC, Boutouyrie P, Bouchard P. Periodontitis and arterial stiffness: a systematic review and meta-analysis. J Clin Periodontol. 2015;42:977–87.

  91. 91.

    Xu S, Liu B, Yin M, Koroleva M, Mastrangelo M, Ture S, et al. A novel TRPV4-specific agonist inhibits monocyte adhesion and atherosclerosis. Oncotarget. 2016;7:37622–35.

  92. 92.

    Ye L, Kleiner S, Wu J, Sah R, Gupta RK, Banks AS, et al. TRPV4 is a regulator of adipose oxidative metabolism, inflammation, and energy homeostasis. Cell. 2012;151:96–110.

  93. 93.

    Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468–71.

  94. 94.

    Jawien J. The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis. Curr Pharm Biotechnol. 2012;13:2435–9.

  95. 95.

    Ratner BD. A pore way to heal and regenerate: 21st century thinking on biocompatibility. Regen Biomater. 2016;3:107–10.

  96. 96.

    Major MR, Wong VW, Nelson ER, Longaker MT, Gurtner GC. The foreign body response: at the interface of surgery and bioengineering. Plast Reconstr Surg. 2015;135:1489–98.

  97. 97.

    Velnar T, Bunc G, Klobucar R, Gradisnik L. Biomaterials and host versus graft response: a short review. Bosn J Basic Med Sci. 2016;16:82–90.

  98. 98.

    Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20:86–100.

  99. 99.

    Moore LB, Kyriakides TR. Molecular characterization of macrophage-biomaterial interactions. Adv Exp Med Biol. 2015;865:109–22.

  100. 100.

    Browne S, Pandit A. Biomaterial-mediated modification of the local inflammatory environment. Front Bioeng Biotechnol. 2015;3:67.

  101. 101.

    Brown BN, Ratner BD, Goodman SB, Amar S, Badylak SF. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials. 2012;33:3792–802.

  102. 102.

    Castelino FV, Varga J. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. Curr Opin Rheumatol. 2014;26:607–14.

  103. 103.

    Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis–a lethal component of systemic sclerosis. Nat Rev Rheumatol. 2014;10:390–402.

  104. 104.

    Trojanowska M. Noncanonical transforming growth factor β signaling in scleroderma fibrosis. Curr Opin Rheumatol. 2009;21:623–9.

  105. 105.

    Tschumperlin DJ. Fibroblasts and the ground they walk on. Physiology. 2013;28:380–90.

  106. 106.

    Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44:450–62.

  107. 107.

    Sharma S, Goswami R, Zhang DX, Rahaman SO. TRPV4 regulates matrix stiffness and TGFβ1-induced epithelial-mesenchymal transition. J Cell Mol Med. 2019;23:761–74.

  108. 108.

    Matterne U, Strassner T, Apfelbacher CJ, Diepgen TL, Weisshaar E. Measuring the prevalence of chronic itch in the general population: development and validation of a questionnaire for use in large scale studies. Acta Derm Venereol. 2009;89:250–6.

  109. 109.

    Luo J, Feng J, Liu S, Walters ET, Hu H. Molecular and cellular mechanisms that initiate pain and itch. Cell Mol Life Sci. 2015;72:3201–23.

  110. 110.

    Alessandri-Haber N, Yeh JJ, Boyd AE, Parada CA, Chen X, Reichling DB, et al. Hypotonicity induces TRPV4-mediated nociception in rat. Neuron. 2003;39:497–511.

  111. 111.

    Bang S, Yoo S, Yang TJ, Cho H, Hwang SW. Nociceptive and pro-inflammatory effects of dimethylallyl pyrophosphate via TRPV4 activation. Br J Pharmacol. 2012;166:1433–43.

Download references


SOR was supported by a NIH grant (1R01EB024556-01), and NSF grant (CMMI-1662776).

Author information

Correspondence to Shaik O. Rahaman.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dutta, B., Arya, R.K., Goswami, R. et al. Role of macrophage TRPV4 in inflammation. Lab Invest 100, 178–185 (2020).

Download citation